Write in a clean editor, then format for Lymphatics in one click — DocuGuru applies the official MDPI template with numbered references and exports a submission-ready PDF plus the editable LaTeX source. Free to start.
Lymphatics is a peer-reviewed journal published by MDPI, covering Lymphatic System and Diseases, Lymphoma Diagnosis and Treatment, Chronic Lymphocytic Leukemia Research. Over its lifetime it has published 123 papers, which have received 168 citations.
| Publisher | MDPI |
|---|---|
| Reference style | Numbered (MDPI) Numbered — [1], [2] in the text 1. Smith, A.; Jones, B.; Lee, C. A Representative Article Title. Lymphatics 2023, 12, 45–58.
Formats any DOI in Lymphatics style. No sign-up. |
| Publishes research in | Lymphatic System and Diseases Lymphoma Diagnosis and Treatment Chronic Lymphocytic Leukemia Research Lymphatic Disorders and Treatments Acute Lymphoblastic Leukemia research |
| ISSN | 2813-3307 |
| Citation impact (2-yr) | 0.82 |
| h-index | 6 |
| i10-index | 4 |
| Open access | Yes — indexed in DOAJ |
| Top institutions publishing here | The University of Texas MD Anderson Cancer Center |
| You get | A submission-ready PDF and the editable LaTeX source — ready to submit. |
Citations each year’s papers have accumulated so far — the most recent years are still building up.
Lymph node status is an important prognostic factor in multiple oncologic conditions in humans and companion animals. In addition, the resection of the affected nodes can have a substantial therapeutic effect on various cancer subtypes in both species. Given the impact on prognosis and management, it is paramount to identify and remove affected nodes. While…
Early detection and treatment can slow the progression of lymphedema. To diagnose lymphedema in the subclinical phase, a sensitive imaging modality is required. Radioisotope-based lymphoscintigraphy (LSG) has been the “gold standard” for a century. Indocyanine green lymphography (ICGL) is being used at our institute for diagnosing and grading all lymphedema patients. In this study, ICGL…
Anti-CD20 monoclonal antibodies (mAbs) have revolutionized the treatment of lymphomas by improving the survival of patients, particularly in conjunction with chemotherapy. Until recently, the gold standard was based on the utilization of Rituximab (RTX) combined with chemotherapy. With our better understanding of monoclonal antibody (mAb) engineering, anti-CD20 mAb therapy has evolved to enhance clinical outcomes…
The diagnosis and treatment of lymphoid neoplasms have undergone a continuously progressive positive change in the last three decades, with accelerated progress in the previous decade due to the advent of genomics in cancer diagnosis. Significantly, there has been an increasing emphasis on integrating molecular genetics with clinical, morphological, immunophenotypic, and cytogenetic evaluation for diagnosis.…
The diagnosis and treatment of lymphoid neoplasms have undergone a progressively positive change in the last three decades, with accelerated progress in the previous decade due to the advent of genomics in cancer diagnosis. Significantly, there has been an increasing emphasis on integrating molecular genetics with clinical, morphologic, immunophenotypic, and cytogenetic evaluation for diagnosis. As…
